Do Antiangiogenics Promote Clot Instability? Data from the TESEO Prospective Registry and Caravaggio Clinical Trial

Alberto Carmona-Bayonas[1]   Melina Verso[2]   Manuel Sánchez Cánovas[1]   Jaime Rubio Pérez[3]
Marta García de Herreros[4]   Purificación Martínez del Prado[5]   Isaura Fernández Pérez[6]
Teresa Quintanar Verduguez[7]   Berta Obispo Portero[8]   Vanessa Pachón Olmos[9]   David Gómez[10]
Laura Ortega[11]   Marta Serrano Moyano[12]   Elena M. Brozos[13]   Mercedes Biosca[14]   Maite Antonio Rebollo[15]
Lucía Teijeira Sanchez[16]   Carolina Hernández Pérez[17]   José David Cumplido Burón[18]   Nieves Martínez Lago[19]
Estefanía García Pérez[20]   Jose Muñoz Langa[21]   Pedro Pérez Segura[22]   Eva Martínez de Castro[23]
Paula Jimenez-Fonseca[10]   Giancarlo Agnelli[24]   Andrés Muñoz[10]

[1] Hematology and Medical Oncology Department, Hospital Universitario Morales Meseguer, University of Murcia, IMIB, Murcia, Spain
[2] Medicina Vascolare e d'Urgenza, Ospedale S. Maria della Misericordia, Università di Perugia, Perugia, Italy
[3] Medical Oncology Department, Hospital Fundación Jiménez Diaz, Madrid, Spain
[4] Medical Oncology Department, Hospital Clinic, Barcelona, Spain
[5] Medical Oncology Department, Hospital Universitario de Basurto, Bilbao, Spain
[6] Medical Oncology Department, Hospital Álvaro Cunqueiro/Complejo Hospitalario Universitario de Vigo, Vigo, Spain
[7] Medical Oncology Department, Hospital General Universitario de Elche, Elche, Spain
[8] Medical Oncology Department, Hospital Universitario Infanta Leonor, Madrid, Spain
[9] Medical Oncology Department, Hospital Universitario Ramón y Cajal, Madrid, Spain
[10] Medical Oncology Department, Hospital Universitario Central de Asturias, ISPA, Oviedo, Spain
[11] Medical Oncology Department, Hospital Universitario Gregorio Marañon, Madrid, Spain
[12] Medical Oncology Department, Hospital de Especialidades de Jerez de la Frontera, Jerez de la Frontera, Spain
[13] Medical Oncology Department, Complejo Hospitalario Universitario de Santiago, Santiago de Compostela, Spain

Address for correspondence Alberto Carmona-Bayonas, MD, PhD, Hematology and Medical Oncology Department, Centro de Hemodonación de Murcia, Hospital Universitario Morales Meseguer, Calle Marqués de los Vélez s/n, 30008, Murcia, UMU, IMIB, Murcia, Spain (e-mail: alberto.carmonabayonas@gmail.com).

[14] Medical Oncology Department, Hospital Universitario Vall dHebron, Barcelona, Spain
[15] Medical Oncology Department, Instituto Catalán de Oncología (ICO), L'Hospitalet de Llobregat, Llobregat, Spain
[16] Medical Oncology Department, Complejo Hospitalario de Navarra, Pamplona, Spain
[17] Medical Oncology Department, Hospital Universitario Nuestra Señora de la Candelaria, Tenerife, Spain
[18] Medical Oncology Department, Hospital Universitario de Torrevieja, Torrevieja, Spain
[19] Medical Oncology Department, Hospital Clínico Universitario A Coruña, La Coruña, Spain
[20] Medical Oncology Department, Hospital de Barcelona, Barcelona, Spain
[21] Medical Oncology Department, Hospital Clínico Universitario de Valencia, Valencia, Spain
[22] Medical Oncology Department and IdISSC, Hospital Universitario Clínico San Carlos, Madrid, Spain
[23] Medical Oncology Department, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain
[24] Internal Vascular and Emergency Medicine-Stroke Unit, University of Perugia, Perugia, Italy

Abstract

Keywords

► antiangiogenic therapy
► cancer
► clot stability
► pulmonary embolism
► venous thromboembolism

Background Venous thromboembolism (VTE) is a common complication in cancer patients. Much of its morbidity stems from the development of fatal pulmonary embolisms (PE). Little is known about the factors involved in clot stability, with angiogenesis possibly being implicated.

Methods The database is from the TESEO prospective registry that recruits cancer patients with VTE from 41 Spanish hospitals. Independent validation was conducted in a cohort from the Caravaggio trial. The objective is to evaluate the association between exposure to antiangiogenic therapies and the PE/VTE proportion in oncological patients.

Results   In total, 1,536 subjects were evaluated; 58.4% ($n = 894$) had a PE and 7% ($n = 108$) received antiangiogenic therapy (bevacizumab in 75%). The PE/VTE proportion among antiangiogenic-treated individuals was 77/108 (71.3%) versus 817/1,428 (57.2%) among those receiving other alternative therapies ($p = 0.004$). The effect of the antiangiogenics on the PE/VTE proportion held up across all subgroups except for active smokers or those with chronic obstructive pulmonary disease. Exposure to antiangiogenics was associated with increased PEs, odds ratio (OR) 2.27 (95% CI, 1.42–3.63). In the Caravaggio trial, PE was present in 67% of the individuals treated with antiangiogenics, 50% of those who received chemotherapy without antiangiogenic treatment, and 60% without active therapy ($p = 0.0016$).

Conclusion   Antiangiogenics are associated with increased proportion of PE in oncological patients with VTE. If an effect on clot stability is confirmed, the concept of thrombotic risk in cancer patients should be reconsidered in qualitative terms.

Introduction

Deep vein thrombosis (DVT) and pulmonary embolism (PE) are typically considered manifestations of the same physiological process, encompassed under the denomination of venous thromboembolism (VTE).[1] Nevertheless, inasmuch as DVT, in and of itself, is not generally lethal in the short term, PE comprises a life-threatening event when fibrin fragments from the clot occlude enough of the pulmonary arterial territory.[2,3] Despite its clinical relevance, little progress has been made in elucidating the mechanisms associated with clot stability.[4] Nonetheless, factors impacting the viscoelasticity of the fibrin scaffolding must be studied if we are to understand the qualitative consequences of hypercoagulability states, contributing to risk-adapted management.[4,5]

Cancer is among the most common causes of acquired thrombophilia.[6] Oncological patients with VTE suffer increased short-term mortality, occasionally due to the direct effect of PE.[3,7,8] Cancer-related PE entails a 15-day mortality rate of 10.1% (95% confidence interval [CI], 8.4–12.1).[9] Recent years have witnessed emphasis on the need to predict individual thrombotic risk.[10] Even so, thromboprophylaxis in high-risk individuals has failed to improve survival,[11] making new proposals essential. One way to move forward would be to investigate the mechanisms that give rise to thrombotic instability, prioritizing thromboprophylaxis when embolization entails high risk.

Angiogenesis, one of the most relevant hallmarks of cancer[12,13] which is regulated by the haemostatic system,[12] is one of the processes possibly involved. Thus, the transglutaminase activity of factor XIII promotes clot stability and is pro-angiogenic.[14] Antiangiogenics are among the most widely used targeted therapies.[15] With these underpinnings, we have examined the TESEO thrombosis registry of the Spanish Society of Medical Oncology (SEOM) to evaluate whether antiangiogenic therapies are associated with PE in the oncological population. An independent validation was conducted in a cohort from the Caravaggio trial.

Methods

Patients and Study Design

TESEO is an observational study sponsored by SEOM that prospectively and consecutively recruits patients at 41 Spanish hospitals. Inclusion criteria comprise being ≥ 18 years of age with a solid tumour and objectively detected VTE (e.g., Doppler ultrasound, computed tomography [CT], angiography scans, scheduled CT to assess tumour response, etc.). Exclusion criteria include superficial thrombophlebitis, the appearance of VTE prior to cancer diagnosis or after completing adjuvant treatment (>1 month in both cases). The study was approved by the Research Ethics Committee of all the Autonomous Communities and participating centres. All participants signed a written informed consent form.

The data were validated in patients from the randomized Caravaggio trial, the rationale and design of which have been previously published.[16] Essentially, it is a non-inferiority phase III study that recruited subjects with cancer and incidental or symptomatic VTE. This population was randomized to receive apixaban or dalteparin. All the participants with active cancer at the time of VTE, except for those with haematological diseases, were selected for the validation. The scientific committee and independent statistical team analysed the results separately.

Objectives and Variables

The objective is to examine the association between the use of antiangiogenic therapies and PE/VTE proportion. PE was defined in the registry as an intraluminal contrast-filling defect measuring ≥ 2 mm visualized on two CT sections (CT pulmonary angiography or conventional contrast enhanced CT scans). In the event of isolated subsegmental PEs, investigators were required to verify the information with a thoracic radiologist. Diagnosis by Doppler ultrasound followed the usual criteria (e.g., non-compressibility, intraluminal thrombus, flow abnormality, etc.) according to the practice of each centre. Diagnostic criteria in the Caravaggio trial were comparable.[16]

Antiangiogenic therapy was considered to comprise any drug (antibody or tyrosine kinase inhibitor [TKI]) targeting any molecule pertaining to the family of vascular endothelial growth factor (VEGF), its receptors, or other analogous molecules involved in angiogenesis.[15] In both cohorts (TESEO and Caravaggio), antineoplastic treatment was defined as the therapy the patient was receiving at the time of thrombosis or had completed in the 30 days prior.

To appraise the association, model-building was performed by means of subject-matter knowledge regarding causal mechanisms or sources of bias.[17] The candidate predictors for the multivariable model were initially chosen after a review of the literature and conversation with the executive committee of the TESEO registry, made up of medical oncologists with expertise in thrombosis and cancer. Thus, variables that could theoretically affect the appearance or diagnosis of PE were selected as confounding factors or mediators: suspected VTE, prior VTE, associated chemotherapy, tumour type (colorectal vs. others), tumour stage TMN (IV vs. others), Eastern Cooperative Oncology Group Performance Status (ECOG-PS), and age. Other variables evaluated were the concurrent presence of DVT and PE characteristics (e.g., site, extension, association with symptoms).

Sensitivity analyses were also performed to examine how different factors influenced the conclusions. The point of these analyses is to get more tenable results if the magnitude of benefit did not change on the basis of the stratification factors (e.g., the association holds when only the CT-detected incidental events are considered). The selection criterion for these factors was based on the assumption that the PE detection patters would be more homogeneous within each category, thereby probing the possibility of detection biases. To this end, bivariate analyses were used, stratified by the presence of active cancer, tumour stage, tumour type, type of antiangiogenic, cancer treatment, type of diagnosis (suspected vs. not suspected), diagnostic method (CTPA, scheduled or unplanned CT), presence of recurring events, active smoking, comorbidities, and the use of antiplatelets agents. Other end points consisted of rate of venous rethrombosis and major/clinically relevant bleeding, as per the International Society on Thrombosis and Haemostasis (ISTH). Rethrombosis was defined as the appearance of a second thrombotic event following proper management of the index VTE or progression of the previous episode despite appropriate anticoagulant therapy.

Statistical Methods

The Aalen–Johansen estimator was used to obtain the cumulative incidence function for rethrombosis and bleeding, in the presence of death as a competing event. Standard descriptive statistics were used, including absolute and relative frequencies, and differences in proportions. We provided 95% CIs when appropriate and considered a significance level of $p < 0.05$ in all statistical tests. Two-tailed p-values were calculated. Comparisons between proportions were conducted by bivariate χ^2-tests. Inference was accompanied by sensitivity analyses contemplating other factors that could impact results (see above). The

association between PE and antiangiogenic therapy was further assessed by means of multivariable binary logistic regression, specified with the previously mentioned covariates. These descriptive analyses were executed using R version 4.01.[18]

Results

Patient Characteristics

The TESEO registry database contains 1,536 subjects with VTE diagnosed between July 2018 and December 2020. Of them, 58.2% ($n = 894$) had a PE, whereas 41.8% ($n = 642$) had other VTEs. Other concurrent thromboses were present in 174/894 (19.4%) of the patients with PE. At the time of VTE, 7% of the individuals ($n = 108$) were receiving antiangiogenic therapy. Baseline characteristics are displayed in ►**Table 1**. PEs were most often diagnosed by conventional CT scan (either scheduled or unplanned) performed for reasons other than suspicion of PE in 59.6% ($n = 533$), followed by CT pulmonary angiography in 35.2% ($n = 315$) (see diagnostic methods in ►**Supplementary Appendix Table 1**, available in the online version). The most common antiangiogenics were antibodies (bevacizumab in 81, ramucirumab in 2), VEGF trap (aflibercept in 10), or TKIs (cabozantinib in 4; sunitinib in 3; sorafenib in 2; axitinib, pazopanib, regorafenib, and vandetanib in one case each, and an unspecified TKI in another 2) (►**Table 2**).

The validation cohort from the Caravaggio trial comprises 1,034 cases. Of them, 56% ($n = 579$) were diagnosed with PE, whereas 44% ($n = 455$) had a DVT. The remaining baseline characteristics can be found in ►**Table 3**. At the time of recruitment, 86/1,034 (8.3%) of the Caravaggio study population were receiving antiangiogenic therapy (►**Table 2**).

Association between PE and Antiangiogenic Therapy in the TESEO Cohort

PE was suffered by 77/108 (71.2%, 95% CI 62.1–78.9%) of the individuals treated with an antiangiogenic versus 817/1428 (57.2%, 95% CI 54.6–59.7%) subjects who were receiving other therapies (difference in proportions, 14.0%, 95% CI, 4.1–22.5%) ($\chi^2 = 8.186$, degrees of freedom [df] = 1, $p = 0.004$) (►**Supplementary Appendix Fig. 1**, available in the online version). To make a preliminary evaluation of possible detection biases, the difference in proportions of subjects with or without an antiangiogenic was calculated in different subgroups. The effect of the antiangiogenic on the proportion of PE was maintained in all cases except in active smokers or patients with chronic obstructive pulmonary disease (COPD) (►**Fig. 1**). In particular, the association held in the subgroup of metastatic cancer and was independent of whether the antiangiogenic was bevacizumab and of diagnostic method (CTPA, scheduled or unplanned CT). Likewise, despite the fact that most of the truly asymptomatic events, as well as symptomatic events for reasons other than the VTE, occurred most often after PE (►**Supplementary Appendix Table 2**, available in the online version), the association between PE diagnosis and the use of antiangiogenics is independent of the presence or absence of these symptoms (►**Fig. 1**). We

Table 1 Baseline characteristics broken down by the use of antiangiogenic (TESEO study)

	Overall	No antiangiogenic, *N* (%)	Antiangiogenic, *N* (%)
Age, median (range)	66 (20–92)	66 (20–92)	66 (28–86)
Sex, male	807 (52.6)	745 (52.2)	62 (57.4)
ECOG-PS			
0	349 (22.7)	328 (23.0)	21 (19.4)
1	801 (52.1)	737 (51.6)	64 (59.3)
2	297 (19.3)	280 (19.6)	17 (15.7)
3	83 (5.4)	77 (5.4)	6 (5.6)
4	6 (0.4)	6 (0.4)	0
Most common tumours			
Colorectum	307 (20)	238 (16.7)	69 (63.9)
Lung—Non-small cell	297 (19.3)	291 (20.4)	6 (5.6)
Breast	160 (10.4)	158 (11.1)	2 (1.9)
Pancreas	146 (9.5)	146 (10.2)	0
Stomach	77 (5.0)	77 (5.3)	2 (1.9)
Ovarian	62 (4.0)	59 (4.1)	3 (2.8)
Bladder	56 (3.6)	56 (3.9)	0
Endometrial	32 (2.1)	30 (2.1)	2 (1.9)
Bile duct/gallbladder	42 (2.7)	42 (2.9)	0
Esophagus	32 (2.1)	32 (2.2)	0
Brain	39 (2.5)	31 (2.2)	8 (7.4)
Prostate	34 (2.2)	34 (2.4)	0
Kidney	25 (1.6)	17 (1.2)	8 (7.4)
Liver	17 (1.1)	14 (1.0)	3 (2.8)
Other	210 (13.6)	203 (14.2)	5 (4.6)
Histology, adenocarcinoma	1075 (70%)	988 (69.2)	87 (80.6)
TNM stage IV	1,091 (71.0)	992 (69.5)	99 (91.7)
Active tumour	1,262 (82.2)	1,161 (81.3)	101 (93.5)
Use of chemotherapy	889 (57.9)	805 (56.4)	84 (77.8)
VTE, type of detection			
Suspected	747 (48.6)	701 (49.1)	46 (42.6)
Unsuspected	771 (50.2)	709 (49.6)	62 (57.4)
Unknown	18 (1.2)	18 (1.3)	0
Type of VTE			
DVT	642 (41.8)	611 (42.8)	31 (28.7)
PE + without DVT	720 (46.9)	656 (45.9)	64 (59.3)
PE + DVT	174 (11.3)	161 (11.3)	13 (12.0)
Severity, NCI-CTC			
Grade 1	–	–	–
Grade 2	682 (44.9)	647 (45.9)	35 (32.4)
Grade 3	780 (51.4)	709 (50.3)	71 (65.7)
Grade 4	47 (3.1)	45 (3.2)	2 (1.9)
Grade 5	9 (0.6)	9 (0.6)	0
Unknown	18 (1.1)	18 (1.2)	0
Total	1,536 (100%)	1,428 (100%)	108 (100%)

Abbreviations: DVT, deep vein thrombosis; ECOG-PS, Eastern Cooperative Group Performance Status; NCI-CTC, National Cancer Institute Common Toxicity Criteria; PE, pulmonary embolism; TNM, tumour, node, metastases; VTE, venous thromboembolism.

Table 2 Antiangiogenic drugs

	TESEO registry, N (%)	Caravaggio trial, N (%)
Aflibercept (recombinant fusion protein)	10 (9.2)	4 (4.7)
Bevacizumab (antiangiogenic monoclonal antibody)	81 (75.0)	30 (34.9)
Ramucirumab (antiangiogenic monoclonal antibody)	2 (1.8)	2 (2.3)
Axitinib (tyrosine kinase inhibitor)	1 (0.9)	0
Cabozantinib (tyrosine kinase inhibitor)	4 (3.7)	1 (1.2)
Imatinib (tyrosine kinase inhibitor)	0	1 (1.2)
Lenvatinib (tyrosine kinase inhibitor)	0	0
Pazopanib (tyrosine kinase inhibitor)	1 (0.9)	3 (3.5)
Sorafenib (tyrosine kinase inhibitor)	2 (1.8)	0
Sunitinib (tyrosine kinase inhibitor)	3 (2.7)	2 (2.3)
Regorafenib (tyrosine kinase inhibitor)	1 (0.9)	2 (2.3)
Vandetanib (tyrosine kinase inhibitor)	1 (0.9)	0
Other, not specified	2 (1.8)	84 (97.7)
Total	108	86

Notes: N, number of patients taking antiangiogenic therapy at randomization. Patients were included in only one treatment group. Percentages were calculated on total number of patients taking antiangiogenic therapies at randomization. Subjects with haematological cancer and history of cancer were excluded from analysis.

then fitted a multivariable binary logistic regression (►**Fig. 2**, ►**Supplementary Appendix Table 3**, available in the online version). In this model, exposure to antiangiogenics was associated with a higher proportion of PE with an odds ratio (OR) of 2.27 (95% CI, 1.42–3.63). While other confounding factors were significant, the model was not causally specified to make inferences in that regard (►**Fig. 2**). The detailed breakdown of thrombosis locations does not support the notion that the association between PE and antiangiogenics is dependent on the more proximal location of lower limb thrombosis in subjects who have received these therapies, given that the proportion of DVT at the femoral-iliac level is comparable in both groups (►**Supplementary Appendix Table 4**, available in the online version). A sensitivity analysis revealed that the association persisted when the antineoplastic treatment was categorized as 'non-antiangiogenic', 'treatment with antiangiogenic', and 'no therapy' with PE in 56.0% (95% CI, 52.8–59.1) (521/930), 71.2% (95% CI, 62.1–78.9) (77/108) and 59.4% (95% CI, 55.0–63.6%) (296/498), respectively ($\chi2 = 9.742$, df $= 2$, $p = 0.007$).

Characteristics of VTE and Prognosis

In patients with PE, the data do not contradict the hypothesis that the rate of multiple (47.9 vs. 41.6%, $\chi2 = 1.12$, df $= 1$, p-value $= 0.289$) or central PEs (58.4 vs. 67.5%, $\chi2 = 2.43$, df $= 1$, p-value $= 0.118$) is similar in subjects without versus with antiangiogenics, respectively. The 12-month cumulative incidence of venous rethrombosis was 6.2% (95% CI, 4.8–7.8) and 5.2% (95% CI, 1.6–11.8), for subjects with or without antiangiogenics, respectively (Fine-Gray test, p-value $= 0.852$). The cumulative incidence of clinically relevant or major bleeding was 6.7% (95% CI, 5.4–8.3) versus 4.3% (95% CI, 1.4–10.0) with or without antiangiogenic therapy, respectively (Fine-Gray test, p-value $= 0.425$). Finally, median over-

all survival (OS) in patients with stage IV tumours with any VTE was 18.6 months (95% CI, 10.5–NA) versus 9.2 months (95% CI, 8.1–10.7) in subjects with or without antiangiogenics, respectively (log-rank test, p-value $= 0.02$).

Validation in the Caravaggio Trial

At the time of randomization, 56/86 of the individuals treated with antiangiogenic therapy (65.1%), 218/438 who received chemotherapy without any antiangiogenic (49.7%), and 305/510 of the participants without active treatment (59.8%) had PE ($\chi2 = 12.791$, df $= 2$, p-value $= 0.0016$).

Discussion

Antiangiogenic drugs have been used as antitumour therapy for more than 20 years, but their association with venous thrombotic risk remains unclear. An initial meta-analysis found that individuals treated with bevacizumab suffered more VTE with a relative risk of 1.33 (95% CI, 1.13–1.56) with respect to subjects treated with other therapies.[19] In a second meta-analysis, Hurwitz et al found no differences in incidence of all-grade VTEs for bevacizumab versus controls.[20] Extending to the rest of antiangiogenics, Abdel-Qadir et al found insufficient evidence to contradict the null hypothesis (similar thrombotic risk), although the margins of error were compatible with substantially increased odds, hence, the 'absence of effect' interpretation could require additional data. (e.g., for DVT, OR 1.20, 95% CI, 0.86–1.66).[21] One notable limitation was that most randomized controlled trials (RCTs) did not report the type of thromboembolism, preventing the PE/VTE proportion from being estimated. In a third meta-analysis, Liu et al found PE to be uncommon in RCTs of antiangiogenics (approximately 1.7%),[22] impeding the ability to capture how the PE/VTE proportion varied based on

Table 3 Outcomes and characteristics in the validation cohort (Caravaggio trial)

	Overall	At least one antiangiogenic therapy at randomization, N (%)	At least one therapy other than antiangiogenic at randomization, N (%)	No therapy at randomization, N (%)
Age, median	69	64	69	69
Sex, male	505 (48.8)	42 (48.8)	207 (47.3)	256 (50.2)
Most common tumours				
Colorectum	229 (22.1)	26 (30.2)	107 (24.4)	96 (18.8)
Lung	195 (18.9)	30 (34.9)	57 (13.0)	108 (21.2)
Genitourinary	134 (13.0)	7 (8.1)	55 (12.6)	72 (14.1)
Breast	149 (14.4)	9 (10.5)	88 (20.1)	52 (10.2)
Pancreatic or Hepatobiliary	86 (8.3)	0	43 (9.8)	43 (8.4)
Gynaecological	114 (11.0)	5 (5.8)	44 (10.0)	65 (12.7)
Upper GI	54 (5.2)	5 (5.8)	22 (5.0)	27 (5.3)
Head and Neck	20 (1.9)	0	10 (2.3)	10 (2.0)
Bone/Soft Tissue	13 (1.3)	0	5 (1.1)	8 (1.6)
Skin - Melanoma	10 (1.0)	1 (1.2)	2 (0.5)	7 (1.4)
Other	30 (2.9)	3 (3.5)	5 (1.1)	22 (4.3)
TNM stage IV (metastatic)	503 (48.6)	61 (70.9)	220 (50.2)	222 (43.5)
Active tumour	1,034 (100)	86 (100)	438 (100)	510 (100)
VTE, type of detection				
Symptomatic	819 (79.2)	63 (73.3)	352 (80.4)	404 (79.2)
Unsuspected	215 (20.8)	23 (26.7)	86 (19.6)	106 (20.8)
Type of VTE				
DVT	455 (44.0)	30 (34.9)	220 (50.2)	205 (40.2)
PE + without DVT	493 (47.7)	53 (61.6)	184 (42.0)	256 (50.2)
PE + DVT	86 (8.3)	3 (3.5)	34 (7.8)	49 (9.6)
Total	1,034	86	438	510

Abbreviations: DVT, deep vein thrombosis; PE, pulmonary embolism; TNM, tumour, node, metastases; VTE, venous thromboembolism.
Notes: Percentages were calculated on total number of patients in each group. Subjects with haematological cancer and history of cancer were excluded from analysis.

these treatments. However, thromboembolism is not a common side effect in clinical trials, patients are not generally asked specifically about them, and half of all cases are asymptomatic. Therefore, it is likely that VTEs are underdiagnosed.[23]

Our study differs from those analyses as it does examine the relative frequency of PEs across subjects who have had any VTE and, consequently, makes it possible to probe into the qualitative characteristics of the events in a broad, prospective cohort. Mainly, we have found that exposure to antiangiogenics was associated with a marked increase in the proportion of PE over DVT. This was consistent across all subgroups, except for active smokers and subjects with COPD. These results were confirmed in the Caravaggio clinical trial.

The hypothesis put forth by our study is compelling because it carries a prediction regarding the role of the VEGF/VEGFR signalling pathway on clot stability and embolic load that can be tested using an animal model. The literature includes some mechanisms that would account for the disparate incidence of DVT and PE in specific situations, generally involving abnormal fibrinolysis or the transglutaminase activity of factor XIII (FXIIIa, or fibrin stabilizing factor).[24] Thus, thromboses in the context of factor V Leiden have been reported as unlikely to embolize given the increased activity of FXIIIa induced by thrombin.[24] In contrast, Shaya et al have demonstrated that direct thrombin inhibitors decrease clot stability in a murine model of thrombosis, raising the associated embolic load.[5] Nevertheless, this mechanism would not explain the variation of embolization risk in other thrombophilic defects[25] or other, more general hypercoagulability states, making it necessary to look for other possible explanations. Key to this is that FXIIIa has a pro-angiogenic effect through the crosslink of αvβ3 integrin with VEGFR-2, which entails the ligand-independent activation of VEGFR-2.[14,26] VEGFR-2 phosphorylation also appears to control the pro-angiogenic activity of FXIIIa.[26] However, it is not clear how antiangiogenic therapy affects the

Fig. 1 Differences between proportions of pulmonary embolism with or without antiangiogenic. Positive differences indicate more embolisms in subjects receiving an antiangiogenic. Newcombe's method was used to calculate the confidence interval for the difference between proportions. TNM, tumour, node, metastases; VTE, venous thromboembolism; CT, computed tomography; DVT, deep vein thrombosis; COPD, chronic obstructive pulmonary disease; PE, pulmonary embolism.

transglutaminase activity of FXIIIa, thereby affecting clot stability. Further, the interaction between antiangiogenics and the haemostatic system is possibly more complex, involving other elements, such as the endothelium, platelet adhesion, induction of plasminogen activator inhibitor-1, etc.[27,28] Moreover, the relationship between active smoking and antiangiogenic therapy has not yet been resolved, although some exploratory analyses point toward a decreased therapeutic benefit in smokers.[29] In any event, active smoking per se is associated with resistance to thrombolysis,[30] which would offset the destabilizing effect of the antiangiogenic.

If confirmed, this observation could have practical implications such as prioritizing prevention of potentially fatal episodes, mainly those associated with PE. While attributing fatality to the PE can be complex,[31] the use of dalteparin

lowered the rate of lethal thrombosis from 8% to 0 in the FRAGEM RCT,[32] which would possibly translate to improved OS in an adequately powered trial.

Our study has various limitations. We have ruled out possible detection bias of incidental VTE to the best of our ability, although we cannot definitively exclude the possibility of a case being missed. In any case, the data presented here are subanalyses of two different prospective studies, conducted in different settings, which in total encompass the experience of more than 2,570 participants. The fact that the association holds up across multiple subgroups with presumably homogeneous detection patterns (e.g., similar use of CT to re-evaluate response to anticancer therapy, etc.) reduces the possibility of bias. Be that as it may, our results have generated a hypothesis that must be confirmed

Odds Ratio (66%, 95%, 99% CI)

Fig. 2 Binary logistic regression. The dichotomous response variable is the detection of pulmonary embolism. ECOG PS, Eastern Cooperative Group Performance Status; VTE, venous thromboembolism; TNM, tumour, node, metastases.

experimentally. As for generalizing the results to all antiangiogenics, it must be remembered that bevacizumab comprised 75%, most often used to treat advanced colorectal cancer.

In conclusion, antiangiogenic therapy was associated with an increased PE/VTE proportion in cancer patients. If these results are confirmed, the description of this new phenomenon should inform experimental studies to elucidate the mechanism that modifies clot stability, which would require the concept of thrombotic risk to be redefined, based on the qualitative impact with implications for thromboprophylaxis in oncological patients.

What is known about this topic?

- Pulmonary embolism (PE) and deep vein thrombosis (DVT) have been assumed to share a similar pathophysiological substrate.
- The mechanisms associated with clot stability and those that prevent embolization have yet to be adequately elucidated.
- No clear molecular links between pro-angiogenic mechanisms and processes promoting clot stability are currently known.
- Inasmuch as the incidence of PE in clinical trials of anti-angiogenic drugs has been low, it has not been possible to establish any causal association.

What does this paper add?

- Antiangiogenics appear to promote clot instability, fostering the development of pulmonary embolisms in both the prospective TESEO registry and the Caravaggio RCT.
- The effect of antiangiogenics on clot stability was maintained in all subgroups except in active smokers
- This should inform experimental studies to elucidate the mechanism that modifies clot stability.

References
1 Heit JA, Silverstein MD, Mohr DN, Petterson TM, O'Fallon WM, Melton LJ III. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med 2000;160(06):809–815
2 Heit JA, Silverstein MD, Mohr DN, Petterson TM, O'Fallon WM, Melton LJ III. Predictors of survival after deep vein thrombosis and pulmonary embolism: a population-based, cohort study. Arch Intern Med 1999;159(05):445–453
3 Carmona-Bayonas A, Jiménez-Fonseca P, Font C, et al. Predicting serious complications in patients with cancer and pulmonary embolism using decision tree modelling: the EPIPHANY Index. Br J Cancer 2017;116(08):994–1001
4 Tutwiler V, Singh J, Litvinov RI, Bassani JL, Purohit PK, Weisel JW. Rupture of blood clots: mechanics and pathophysiology. Sci Adv 2020;6(35):c0496
5 Shaya SA, Saldanha LJ, Vaezzadeh N, Zhou J, Ni R, Gross PL. Comparison of the effect of dabigatran and dalteparin on thrombus stability in a murine model of venous thromboembolism. J Thromb Haemost 2016;14(01):143–152
6 Carmona-Bayonas A, Gómez D, Martínez de Castro E, et al. A snapshot of cancer-associated thromboembolic disease in 2018-2019: first data from the TESEO prospective registry. Eur J Intern Med 2020;78:41–49
7 van der Hulle T, den Exter PL, Planquette B, et al. Risk of recurrent venous thromboembolism and major hemorrhage in cancer-associated incidental pulmonary embolism among treated and untreated patients: a pooled analysis of 926 patients. J Thromb Haemost 2016;14(01):105–113
8 Plasencia-Martínez JM, Carmona-Bayonas A, Calvo-Temprano D, et al. Prognostic value of computed tomography pulmonary angiography indices in patients with cancer-related pulmonary

embolism: data from a multicenter cohort study. Eur J Radiol 2017;87:66–75

9 Carmona-Bayonas A, Jiménez-Fonseca P, Garrido M, et al. Multi-state models: accurate and dynamic methods to improve predictions of thrombotic risk in patients with cancer. Thromb Haemost 2019;119(11):1849–1859

10 Pabinger I, Thaler J, Ay C. Biomarkers for prediction of venous thromboembolism in cancer. Blood 2013;122(12):2011–2018

11 Khorana AA, Soff GA, Kakkar AK, et al; CASSINI Investigators. Rivaroxaban for thromboprophylaxis in high-risk ambulatory patients with cancer. N Engl J Med 2019;380(08):720–728

12 Browder T, Folkman J, Pirie-Shepherd S. The hemostatic system as a regulator of angiogenesis. J Biol Chem 2000;275(03):1521–1524

13 Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144(05):646–674

14 Dardik R, Loscalzo J, Inbal A. Factor XIII (FXIII) and angiogenesis. J Thromb Haemost 2006;4(01):19–25

15 Al-Husein B, Abdalla M, Trepte M, Deremer DL, Somanath PR. Antiangiogenic therapy for cancer: an update. Pharmacotherapy 2012;32(12):1095–1111

16 Agnelli G, Becattini C, Meyer G, et al; Caravaggio Investigators. Apixaban for the treatment of venous thromboembolism associated with cancer. N Engl J Med 2020;382(17):1599–1607

17 Harrell F. Regression Modeling Strategies: with Applications to Linear Models, Logistic and Ordinal Regression, and Survival Analysis. 2nd ed. New York: Springer; 2015

18 R Core Team. R: A Language and Environment for Statistical Computing. Vienna, Austria: R. Foundation for Statistical Computing; 2014

19 Nalluri SR, Chu D, Keresztes R, Zhu X, Wu S. Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis. JAMA 2008;300(19):2277–2285

20 Hurwitz HI, Saltz LB, Van Cutsem E, et al. Venous thromboembolic events with chemotherapy plus bevacizumab: a pooled analysis of patients in randomized phase II and III studies. J Clin Oncol 2011;29(13):1757–1764

21 Abdel-Qadir H, Ethier J-L, Lee DS, Thavendiranathan P, Amir E. Cardiovascular toxicity of angiogenesis inhibitors in treatment of malignancy: a systematic review and meta-analysis. Cancer Treat Rev 2017;53:120–127

22 Liu M, Zheng Y, Chen Z, et al. Risk of severe pulmonary embolism in cancer patients receiving bevacizumab: results from a meta-analysis of published and unpublished data. Tumor Biol 2017;39:1010428317714897

23 Kotlowska MP, Cabezón L, Custodio-Cabello S. Thrombosis incidence in cancer patients treated with antiangiogenic therapy. Ann Oncol 2020:S1052

24 Corral J, Roldán V, Vicente V. Deep venous thrombosis or pulmonary embolism and factor V Leiden: enigma or paradox. Haematologica 2010;95(06):863–866

25 Mäkelburg ABU, Veeger NJGM, Middeldorp S, et al. Different risk of deep vein thrombosis and pulmonary embolism in carriers with factor V Leiden compared with non-carriers, but not in other thrombophilic defects. Results from a large retrospective family cohort study. Haematologica 2010;95(06):1030–1033

26 Dardik R, Loscalzo J, Eskaraev R, Inbal A. Molecular mechanisms underlying the proangiogenic effect of factor XIII. Arterioscler Thromb Vasc Biol 2005;25(03):526–532

27 Verheul HMW, Jorna AS, Hoekman K, Broxterman HJ, Gebbink MF, Pinedo HM. Vascular endothelial growth factor-stimulated endothelial cells promote adhesion and activation of platelets. Blood 2000;96(13):4216–4221

28 Chen N, Ren M, Li R, et al. Bevacizumab promotes venous thromboembolism through the induction of PAI-1 in a mouse xenograft model of human lung carcinoma. Mol Cancer 2015;14:140

29 Mitchell P, Mok T, Barraclough H, Strizek A, Lew R, van Kooten M. Smoking history as a predictive factor of treatment response in advanced non-small-cell lung cancer: a systematic review. Clin Lung Cancer 2012;13(04):239–251

30 Ząbczyk M, Królczyk G, Czyżewicz G, et al. Altered fibrin clot properties in advanced lung cancer: strong impact of cigarette smoking. Med Oncol 2019;36(04):37

31 Tritschler T, Kraaijpoel N, Girard P, et al; Subcommittee on Predictive and Diagnostic Variables in Thrombotic Disease. Definition of pulmonary embolism-related death and classification of the cause of death in venous thromboembolism studies: Communication from the SSC of the ISTH. J Thromb Haemost 2020;18(06):1495–1500

32 Maraveyas A, Waters J, Roy R, et al. Gemcitabine versus gemcitabine plus dalteparin thromboprophylaxis in pancreatic cancer. Eur J Cancer 2012;48(09):1283–1292